Dendrimer-based Macromolecular MRI Contrast Agents: Characteristics and Application
暂无分享,去创建一个
[1] Wolfgang Ebert,et al. Pharmacokinetics of Gadomer-17, a new dendritic magnetic resonance contrast agent , 2001, Magnetic Resonance Materials in Physics, Biology and Medicine.
[2] H. Weinmann,et al. Gadofluorine 8: initial experience with a new contrast medium for interstitial MR lymphography , 1999, Magnetic Resonance Materials in Physics, Biology and Medicine.
[3] Hisataka Kobayashi,et al. Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and cores. , 2003, Bioconjugate chemistry.
[4] Hisataka Kobayashi,et al. Micro-magnetic resonance lymphangiography in mice using a novel dendrimer-based magnetic resonance imaging contrast agent. , 2003, Cancer research.
[5] M. Brechbiel,et al. Renal tubular damage detected by dynamic micro-MRI with a dendrimer-based magnetic resonance contrast agent. , 2002, Kidney international.
[6] B. Misselwitz,et al. Interstitial Magnetic Resonance Lymphography Using a Polymeric T1 Contrast Agent: Initial Experience With Gadomer-17 , 2002, Investigative radiology.
[7] M. Brechbiel,et al. Rapid accumulation and internalization of radiolabeled herceptin in an inflammatory breast cancer xenograft with vasculogenic mimicry predicted by the contrast-enhanced dynamic MRI with the macromolecular contrast agent G6-(1B4M-Gd)(256). , 2002, Cancer research.
[8] T. Iwanaga,et al. Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. , 2002, Cancer research.
[9] R. Günther,et al. T1-weighted MR-lymphography after intramammary administration of Gadomer-17 in pigs. , 2002, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.
[10] M. Brechbiel,et al. Pharmacokinetics and enhancement patterns of macromolecular MR contrast agents with various sizes of polyamidoamine dendrimer cores , 2001, Magnetic resonance in medicine.
[11] M. Brechbiel,et al. Micro‐MR angiography of normal and intratumoral vessels in mice using dedicated intravascular MR contrast agents with high generation of polyamidoamine dendrimer core: Reference to pharmacokinetic properties of dendrimer‐based MR contrast agents , 2001, Journal of magnetic resonance imaging : JMRI.
[12] Akira Hiraga,et al. Novel liver macromolecular MR contrast agent with a polypropylenimine diaminobutyl dendrimer core: Comparison to the vascular MR contrast agent with the polyamidoamine dendrimer core , 2001, Magnetic resonance in medicine.
[13] K Togashi,et al. Positive effects of polyethylene glycol conjugation to generation‐4 polyamidoamine dendrimers as macromolecular MR contrast agents , 2001, Magnetic resonance in medicine.
[14] M. Brechbiel,et al. 3D MR angiography of intratumoral vasculature using a novel macromolecular MR contrast agent , 2001, Magnetic resonance in medicine.
[15] M. Brechbiel,et al. Novel intravascular macromolecular MRI contrast agent with generation‐4 polyamidoamine dendrimer core: Accelerated renal excretion with coinjection of lysine , 2001, Magnetic resonance in medicine.
[16] M. Brechbiel,et al. Dynamic micro-magnetic resonance imaging of liver micrometastasis in mice with a novel liver macromolecular magnetic resonance contrast agent DAB-Am64-(1B4M-Gd)(64). , 2001, Cancer research.
[17] F. Vögtle,et al. Dendrimers and Dendrons: Concepts, Syntheses, Applications , 2001 .
[18] M. Brechbiel,et al. Avidin-dendrimer-(1B4M-Gd)(254): a tumor-targeting therapeutic agent for gadolinium neutron capture therapy of intraperitoneal disseminated tumor which can be monitored by MRI. , 2001, Bioconjugate chemistry.
[19] R Weissleder,et al. Size optimization of synthetic graft copolymers for in vivo angiogenesis imaging. , 2001, Bioconjugate chemistry.
[20] M. Brechbiel,et al. 3D‐micro‐MR angiography of mice using macromolecular MR contrast agents with polyamidoamine dendrimer core with reference to their pharmacokinetic properties , 2001, Magnetic resonance in medicine.
[21] M. Brechbiel,et al. Comparison of the macromolecular MR contrast agents with ethylenediamine-core versus ammonia-core generation-6 polyamidoamine dendrimer. , 2001, Bioconjugate chemistry.
[22] G. Frija,et al. MR lymphography using iron oxide nanoparticles in rats: Pharmacokinetics in the lymphatic system after intravenous injection , 2000, Journal of magnetic resonance imaging : JMRI.
[23] Daniel H. S. Silverman,et al. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma , 2000, European Journal of Nuclear Medicine.
[24] Martin W. Brechbiel,et al. Monoclonal antibody-dendrimer conjugates enable radiolabeling of antibody with markedly high specific activity with minimal loss of immunoreactivity , 2000, European Journal of Nuclear Medicine.
[25] J. Im,et al. Dynamic contrast-enhanced MR imaging of bacterial abscess and VX2 carcinoma in rabbits: comparison of gadopentetate dimeglumine and a macromolecular contrast agent. , 2000, AJR. American journal of roentgenology.
[26] I. Pastan,et al. Pharmacokinetics of 111In- and 125I-labeled antiTac single-chain Fv recombinant immunotoxin. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[27] E. W. Meijer,et al. Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[28] Magnetic resonance lymphography of profundus lymph nodes with liposomal gadolinium-diethylenetriamine pentaacetic acid. , 2000, Biological & pharmaceutical bulletin.
[29] E C Wiener,et al. Development of a tumor-targeting MR contrast agent using the high-affinity folate receptor: work in progress. , 2000, Investigative radiology.
[30] L. Gordon,et al. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[31] M. Brechbiel,et al. Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody. , 1999, Bioconjugate chemistry.
[32] T L Chenevert,et al. Magnetic resonance angiography with gadomer-17. An animal study original investigation. , 1998, Investigative radiology.
[33] M. Bednarski,et al. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. , 1998, Nature medicine.
[34] E C Wiener,et al. Targeting dendrimer-chelates to tumors and tumor cells expressing the high-affinity folate receptor. , 1997, Investigative radiology.
[35] P. Sontum,et al. Gadolinium(III) DO3A macrocycles and polyethylene glycol coupled to dendrimers : Effect of molecular weight on physical and biological properties of macromolecular magnetic resonance imaging contrast agents , 1997 .
[36] N. van Bruggen,et al. Assessing tumor angiogenesis using macromolecular MR imaging contrast media , 1997, Journal of magnetic resonance imaging : JMRI.
[37] I. Pastan,et al. L-lysine effectively blocks renal uptake of 125I- or 99mTc-labeled anti-Tac disulfide-stabilized Fv fragment. , 1996, Cancer research.
[38] B. Hamm,et al. Magnetic resonance lymphography in rats: effects of muscular activity and hyperthermia on the lymph node uptake of intravenously injected superparamagnetic iron oxide particles. , 1996, Academic radiology.
[39] Shihua Zhao,et al. Carboxymethyl-dextran-gadolinium-DTPA as a blood-pool contrast agent for magnetic resonance angiography. Experimental study in rabbits. , 1996, Investigative radiology.
[40] D M Shames,et al. Mammary carcinoma model: correlation of macromolecular contrast-enhanced MR imaging characterizations of tumor microvasculature and histologic capillary density. , 1996, Radiology.
[41] M. Papisov,et al. Macromolecular intravenous contrast agent for MR lymphography: characterization and efficacy studies. , 1996, Radiology.
[42] R Weissleder,et al. Targeted contrast agents in MR imaging. , 1996, Magnetic resonance imaging clinics of North America.
[43] G. Frija,et al. Capillary leakage of a macromolecular MRI agent, carboxymethyldextran-Gd-DTPA, in the liver: pharmacokinetics and imaging implications. , 1996, Magnetic resonance imaging.
[44] R. Castellino,et al. Characterization of Reactive Versus Tumor-Bearing Lymph Nodes with Interstitial Magnetic Resonance Lymphography in an Animal Model , 1995, Investigative radiology.
[45] Wendy S. Becker,et al. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. , 1995, Cancer research.
[46] R. Weissleder,et al. MR Lymphography with a Lymphotropic T1‐Type MR Contrast Agent: Gd‐DTPA‐PGM , 1995, Magnetic resonance in medicine.
[47] R. Brasch,et al. Contrast-Enhanced Magnetic Resonance Imaging Estimation of Altered Capillary Permeability in Experimental Mammary Carcinomas After X-Irradiation , 1994, Investigative radiology.
[48] P. Singh,et al. Starburst dendrimers: enhanced performance and flexibility for immunoassays. , 1994, Clinical chemistry.
[49] T. Desser,et al. Dynamics of tumor imaging with Gd‐DTPA—polyethylene glycol polymers: Dependence on molecular weight , 1994, Journal of magnetic resonance imaging : JMRI.
[50] R. Weissleder,et al. Detection of pulmonary emboli by using MR angiography with MPEG-PL-GdDTPA: an experimental study in rabbits. , 1994, AJR. American journal of roentgenology.
[51] R. Brasch,et al. Effect of varying the molecular weight of the MR contrast agent Gd‐DTPA‐polylysine on blood pharmacokinetics and enhancement patterns , 1994, Journal of magnetic resonance imaging : JMRI.
[52] R Weissleder,et al. MR lymphography: study of a high-efficiency lymphotrophic agent. , 1994, Radiology.
[53] C. Meares,et al. Immunogenicity in rabbits and mice of an antibody-chelate conjugate: comparison of (S) and (R) macrocyclic enantiomers and an acyclic chelating agent. , 1994, Cancer research.
[54] Martin W. Brechbiel,et al. Metal-chelate-dendrimer-antibody constructs for use in radioimmunotherapy and imaging , 1994 .
[55] P C Lauterbur,et al. Dendrimer‐based metal chelates: A new class of magnetic resonance imaging contrast agents , 1994, Magnetic resonance in medicine.
[56] R. Barth,et al. Boronated starburst dendrimer-monoclonal antibody immunoconjugates: evaluation as a potential delivery system for neutron capture therapy. , 1994, Bioconjugate chemistry.
[57] M. Taupitz,et al. Interstitial MR lymphography with iron oxide particles: results in tumor-free and VX2 tumor-bearing rabbits. , 1993, AJR. American journal of roentgenology.
[58] A. Darkazanli,et al. MR lymphography with iron oxide compound AMI-227: studies in ferrets with filariasis. , 1992, AJR. American journal of roentgenology.
[59] M. Moseley,et al. Magnetic Resonance Imaging Detection of an Experimental Pulmonary Perfusion Deficit Using a Macromolecular Contrast Agent: Polylysine–Gadolinium-DTPA40 , 1992, Investigative radiology.
[60] B. Hamm,et al. MR lymphography with iron oxide particles: dose-response studies and pulse sequence optimization in rabbits. , 1992, AJR. American journal of roentgenology.
[61] R. Brasch,et al. Rationale and applications for macromolecular Gd‐based contrast agents , 1991, Magnetic resonance in medicine.
[62] J A Frank,et al. Functional MR of the kidney , 1991, Magnetic resonance in medicine.
[63] H. Weinmann,et al. In vivo and in vitro evaluation of Gd-DTPA-polylysine as a macromolecular contrast agent for magnetic resonance imaging. , 1991, Investigative radiology.
[64] M. Moseley,et al. Evaluation of Gd-DTPA-labeled dextran as an intravascular MR contrast agent: imaging characteristics in normal rat tissues. , 1990, Radiology.
[65] William A. Goddard,et al. Starburst Dendrimers: Molecular‐Level Control of Size, Shape, Surface Chemistry, Topology, and Flexibility from Atoms to Macroscopic Matter , 1990 .
[66] M. Moseley,et al. Contrast-enhanced MRI of tumors. Comparison of Gd-DTPA and a macromolecular agent. , 1989, Investigative radiology.
[67] J A Frank,et al. Gadolinium‐DTPA Enhanced Dynamic MR Imaging in the Evaluation of Cisplatinum Nephrotoxicity , 1989, Journal of computer assisted tomography.
[68] J A Frank,et al. Dynamic Gd-DTPA-enhanced MR imaging of the kidney: experimental results. , 1989, Radiology.
[69] M. Ogan,et al. Albumin labeled with Gd-DTPA: an intravascular contrast-enhancing agent for magnetic resonance blood pool imaging: preparation and characterization. , 1987, Investigative radiology.